Literature DB >> 19246079

Optimization of tissue processing for immunohistochemistry for the detection of human glypican-3.

Hirotake Takai1, Atsuhiko Kato, Takahiro Ishiguro, Yasuko Kinoshita, Yayoi Karasawa, Yoshimi Otani, Masamichi Sugimoto, Masami Suzuki, Hiroaki Kataoka.   

Abstract

Glypican-3 (GPC3) is frequently upregulated in hepatocellular carcinoma (HCC) and data on the expression profile in HCC might be useful for therapeutic decision-making and prognostic prediction. This study was performed using HepG2 xenograft tissues to optimize the tissue processing method for GPC3 immunohistochemistry. The optimization was conducted in terms of using GPC3 immunohistochemistry for biological study of GPC3 (Experiment 1) and as a diagnostic tool (Experiment 2). In Experiment 1, GPC3 immunoreactivity (IR) and tissue architecture were compared among differently fixed and embedded specimens. In Experiment 2, using conventional formalin-fixed paraffin-embedded (FFPE) procedures, the effects of different fixation times and antigen retrieval treatments were assessed. In Experiment 1, the periodate-lysine-paraformaldehyde (PLP)-fixed and AMeX method-embedded (PLP-AMeX) specimen showed superior immunoreactivity and excellent tissue architecture preservation. In contrast, the other specimens, especially frozen specimens, resulted in poor IR. In Experiment 2, specimens fixed for 24h showed better IR than those fixed for 7 days and the most remarkable improvement in IR was achieved after protease treatment. These findings indicate that with GPC3 immunohistochemistry for biological studies, the PLP-AMeX specimen is preferable. For diagnostics using FFPE specimens, the fixation time should not be too long and protease should be used for the antigen retrieval treatment. 2008 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19246079     DOI: 10.1016/j.acthis.2008.11.025

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  7 in total

Review 1.  Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.

Authors:  Yukihiro Haruyama; Hiroaki Kataoka
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  Natural history of age-related retinal lesions that precede AMD in mice fed high or low glycemic index diets.

Authors:  Karen A Weikel; Paul Fitzgerald; Fu Shang; M Andrea Caceres; Qingning Bian; James T Handa; Alan W Stitt; Allen Taylor
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-02       Impact factor: 4.799

Review 3.  Glypican-3: a new target for cancer immunotherapy.

Authors:  Mitchell Ho; Heungnam Kim
Journal:  Eur J Cancer       Date:  2010-11-26       Impact factor: 9.162

4.  Intratumoral reciprocal expression of monocarboxylate transporter 4 and glypican-3 in hepatocellular carcinomas.

Authors:  Kenji Yorita; Akinobu Ohno; Takahiro Nishida; Kazuhiro Kondo; Toshihiko Ohtomo; Hiroaki Kataoka
Journal:  BMC Res Notes       Date:  2019-11-09

5.  Preoperative prediction of glypican-3 positive expression in solitary hepatocellular carcinoma on gadoxetate-disodium enhanced magnetic resonance imaging.

Authors:  Yidi Chen; Yun Qin; Yuanan Wu; Hong Wei; Yi Wei; Zhen Zhang; Ting Duan; Hanyu Jiang; Bin Song
Journal:  Front Immunol       Date:  2022-08-25       Impact factor: 8.786

6.  Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.

Authors:  Masafumi Ikeda; Shinichi Ohkawa; Takuji Okusaka; Shuichi Mitsunaga; Satoshi Kobayashi; Chigusa Morizane; Ikue Suzuki; Shunsuke Yamamoto; Junji Furuse
Journal:  Cancer Sci       Date:  2014-03-25       Impact factor: 6.716

7.  Evaluation for clinical and prognostic implications of glypican-3 and α-fetoprotein in hepatocellular carcinoma: a new subtype?

Authors:  Lin Ye; Dan Li; Yaobing Chen; Xiaolong Yu
Journal:  Transl Cancer Res       Date:  2020-05       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.